COSTEM 2026 Learners’ Questionnaire

Dear COSTEM Participant,

To receive your CME accreditation points for attending the 11th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), please complete the following learner’s questionnaire.

Many thanks,
The COSTEM Secretariat

CONGRESS EVALUATION

1. This event has fulfilled my educational goals and my expected learning outcomes

5 - Agree

3 - Neutral

1 - Disagree

Comment:

2. I have learned information at this event that will help me to improve my practice

5 - Agree

3 - Neutral

1 - Disagree

Comment:

3. The event was well-organised

5 - Agree

3 - Neutral

1 - Disagree

Comment:

4. The education provided at this event consistently was very good or excellent

5 - Agree

3 - Neutral

1 - Disagree

Comment:

5. There was sufficient time for discussions, questions & answers and learner engagement

5 - Agree

3 - Neutral

1 - Disagree

Comment:

6. The information presented consistently was supported by a valid scientific evidence base

5 - Agree

3 - Neutral

1 - Disagree

Comment:

7. The speakers consistently were very good or excellent

5 - Agree

3 - Neutral

1 - Disagree

Comment:

8. The location and venue / the virtual platform of the event were very good or excellent

5 - Agree

3 - Neutral

1 - Disagree

Comment:

9. There was no bias in any of the programmed educational events

5 - Agree

3 - Neutral

1 - Disagree

Comment:

PROGRAM EVALUATION

Session 1: AML and graft manipulation

Friday, October 2, 08:15-09:45

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Will graft manipulation replace PTCy?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Is 3+7 induction in AML prior to alloHSCT still the standard in 2026?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 2: CAR T in NHL

Friday, October 2, 11:40-13:10

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Is in-vivo CAR T the future of CAR T cell therapy in NHL?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Should CAR T be preferred as first choice instead of bispecific antibodies for RR NHL (FL, CLL)?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 3: PTCy and clinical endpoints

Friday, October 2, 15:00-16:30

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Does PTCy as GVHD prophylaxis increase the risk of relapse?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Is GRFS the best endpoint for transplant trials?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 4: Multiple Myeloma

Friday, October 2, 17:00-18:30

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Can we omit autologous HSCT in MRD negative patients?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Should bispecific combination be preferred to CAR T in myeloma?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 5: ALL

Saturday, October 3, 08:30-10:00

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Is there still a role for chemotherapy and transplantation in adult PH + ALL?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Is there still a role for allo in ALL in the era of CAR T cell?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 6: PTLD

Saturday, October 3, 10:20-11:30

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Is PTLD still the problem in the era of modern GVHD prevention?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Should cell therapy be the first-line treatment in PTLD?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 7: Donor selection and GVHD prophylaxis

Saturday, October 3, 11:30-13:00

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Should all donors be screened for germline mutations?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Should PTCy be added to ATLG/ATG to prevent GVHD?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 8: MRD

Saturday, October 3, 15:10-16:40

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Are we ready for personalized pre-allo conditioning regimens for AML based on MRD status?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Is MRD prior to allograft relevant for MDS?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 9: Hemoglobinopathy and aplastic anemia

Saturday, October 3, 17:00-18:30

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Should we go for gene therapy instead of SCT?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Can haplo-identical HSCT be offered as first-line treatment for severe aplastic anemia?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 10: Complications I

Sunday, October 4, 09:00-10:30

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Can peritransplant JAK inhibitor reduce GVHD and cytopenia in patients with myelofibrosis post allograft?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Is transplant-associated TMA an underestimated complication?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Session 11: Complications II

Sunday, October 4, 11:00-12:30

Did you attend this session?(Required)

Yes

What was presented in this session and what is your key take-away?

Controversy: Is combination therapy the future of chronic GVHD?

Please choose which is the better approach based on the arguments made during this session:

Yes

Comment:

Controversy: Does early use of MSC prevent graft failure and GVHD?

Please choose yes or no based on the arguments made during this session:

Yes

Comment:

Consent:(Required)

I hereby confirm the completed form is correct and that I actively attended the 11th COSTEM Congress scientific sessions as marked herein:(Required)

Name (e-signature)

Your Name
Your Name
Your Name

Date

Title(Required)

First Name(Required)

Last Name(Required)

Country of Origin(Required)

EBAH Member number(Required)

Email Address(Required)

COSTEM 2026 Learners’ Questionnaire

COSTEM 2026 Learners’ Questionnaire

CONGRESS EVALUATION

PROGRAM EVALUATION

Session 1: AML and graft manipulation

Session 2: CAR T in NHL

Session 3: PTCy and clinical endpoints

Session 4: Multiple Myeloma

Session 5: ALL

Session 6: PTLD

Session 7: Donor selection and GVHD prophylaxis

Session 8: MRD

Session 9: Hemoglobinopathy and aplastic anemia

Session 10: Complications I

Session 11: Complications II

Congress Venue

Congress Organizers

COSTEM Congress

Congress Venue

Congress Secretariat